Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 15/20 | 0.74 |
| ▸ | P2RX2 | Q9UBL9 | 15/20 | 0.74 |
| ▸ | IDH1 | O75874 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL890861 | 1.00 | P2RX3 (0.74) | P2RX3P2RX2IDH1 | |
| SCHEMBL890860 | 1.00 | P2RX3 (0.74) | P2RX3P2RX2IDH1 | |
| SCHEMBL311293 | 0.86 | P2RX3 (1.00) | P2RX3P2RX2 | |
| SCHEMBL2709974 | 0.86 | P2RX3 (0.77) | P2RX3P2RX2 | |
| SCHEMBL18571631 | 0.86 | P2RX3 (1.00) | P2RX3P2RX2 | |
| SCHEMBL310032 | 0.86 | P2RX3 (1.00) | P2RX3P2RX2 | |
| SCHEMBL2709971 | 0.86 | P2RX3 (0.77) | P2RX3P2RX2 | |
| SCHEMBL18572351 | 0.84 | P2RX3 (1.00) | P2RX3P2RX2 | |
| SCHEMBL311134 | 0.84 | P2RX3 (1.00) | P2RX3P2RX2 | |
| SCHEMBL310849 | 0.84 | P2RX3 (1.00) | P2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170056398-A1 | SUBSTITUTED PYRIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-03-02 | — | — | US | claimed |
| US-8809402-B2 | Oxazolone and pyrrolidinone-substituted biphenyls as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2014-08-19 | — | — | US | claimed |
| EP-2445889-A1 | NOVEL OXAZOLONE AND PYRROLIDINONE-SUBSTITUTED ARYLAMIDES | F. Hoffmann-La Roche AG (CH) | 2012-05-02 | — | — | EP | claimed |
| WO-2010149541-A1 | NOVEL OXAZOLONE AND PYRROLIDINONE-SUBSTITUTED ARYLAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-29 | — | — | WO | claimed |
| US-20100324069-A1 | OXAZOLONE AND PYRROLIDINONE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | CHEN LI | 2010-12-23 | — | — | US | claimed |
| US-20170056398-A1 | SUBSTITUTED PYRIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-03-02 | — | — | US | disclosed |
| US-9512112-B2 | Substituted pyridines as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2016-12-06 | — | — | US | disclosed |
| US-20140323499-A1 | OXAZOLONE AND PYRROLIDINONE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2014-10-30 | — | — | US | disclosed |
| US-8809402-B2 | Oxazolone and pyrrolidinone-substituted biphenyls as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2014-08-19 | — | — | US | disclosed |
| EP-2445889-A1 | NOVEL OXAZOLONE AND PYRROLIDINONE-SUBSTITUTED ARYLAMIDES | F. Hoffmann-La Roche AG (CH) | 2012-05-02 | — | — | EP | disclosed |
| WO-2010149541-A1 | NOVEL OXAZOLONE AND PYRROLIDINONE-SUBSTITUTED ARYLAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-29 | — | — | WO | disclosed |
| US-20100324069-A1 | OXAZOLONE AND PYRROLIDINONE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | CHEN LI | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323499-A1 | OXAZOLONE AND PYRROLIDINONE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX1 | P2RX3 1/4885P2RX2 2/4885IDH1 1694/4885 |
| US-20100324069-A1 | OXAZOLONE AND PYRROLIDINONE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX1 | P2RX3 1/4885P2RX2 2/4885IDH1 1694/4885 |
| US-20170056398-A1 | SUBSTITUTED PYRIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX7 | P2RX3 1/4885P2RX2 2/4885IDH1 1444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.